JP7651451B2 - Pad酵素のインドールおよびアザインドール阻害剤 - Google Patents

Pad酵素のインドールおよびアザインドール阻害剤 Download PDF

Info

Publication number
JP7651451B2
JP7651451B2 JP2021506683A JP2021506683A JP7651451B2 JP 7651451 B2 JP7651451 B2 JP 7651451B2 JP 2021506683 A JP2021506683 A JP 2021506683A JP 2021506683 A JP2021506683 A JP 2021506683A JP 7651451 B2 JP7651451 B2 JP 7651451B2
Authority
JP
Japan
Prior art keywords
methyl
cyclopropylmethyl
methoxy
carbonyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021506683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534108A5 (cg-RX-API-DMAC7.html
JP2021534108A (ja
Inventor
アヌラグ・エス・スリバスタバ
ロバート・ジェイ・チャーニー
ケヒョン・グー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021534108A publication Critical patent/JP2021534108A/ja
Publication of JP2021534108A5 publication Critical patent/JP2021534108A5/ja
Application granted granted Critical
Publication of JP7651451B2 publication Critical patent/JP7651451B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021506683A 2018-08-08 2019-08-07 Pad酵素のインドールおよびアザインドール阻害剤 Active JP7651451B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862715850P 2018-08-08 2018-08-08
US62/715,850 2018-08-08
PCT/US2019/045466 WO2020033520A1 (en) 2018-08-08 2019-08-07 Indole and azaindole inhibitors of pad enzymes

Publications (3)

Publication Number Publication Date
JP2021534108A JP2021534108A (ja) 2021-12-09
JP2021534108A5 JP2021534108A5 (cg-RX-API-DMAC7.html) 2022-08-16
JP7651451B2 true JP7651451B2 (ja) 2025-03-26

Family

ID=67766306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506683A Active JP7651451B2 (ja) 2018-08-08 2019-08-07 Pad酵素のインドールおよびアザインドール阻害剤

Country Status (18)

Country Link
US (1) US11524959B1 (cg-RX-API-DMAC7.html)
EP (1) EP3833440A1 (cg-RX-API-DMAC7.html)
JP (1) JP7651451B2 (cg-RX-API-DMAC7.html)
KR (1) KR102885181B1 (cg-RX-API-DMAC7.html)
CN (1) CN112805067B (cg-RX-API-DMAC7.html)
AR (1) AR115920A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019319835A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021002091A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108791A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000296A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021001217A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190462A1 (cg-RX-API-DMAC7.html)
IL (1) IL280650A (cg-RX-API-DMAC7.html)
MX (1) MX2021001565A (cg-RX-API-DMAC7.html)
PE (1) PE20211068A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101174RA (cg-RX-API-DMAC7.html)
TW (1) TW202019415A (cg-RX-API-DMAC7.html)
WO (1) WO2020033520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3833440A1 (en) 2018-08-08 2021-06-16 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
ES2956090T3 (es) 2018-08-08 2023-12-13 Bristol Myers Squibb Co Inhibidores de bencimidazol de enzimas PAD
ES2929200T3 (es) 2018-08-08 2022-11-25 Bristol Myers Squibb Co Tienopirroles sustituidos como inhibidores de PAD4
CN115298175B (zh) 2020-02-06 2024-05-07 百时美施贵宝公司 可用作免疫抑制剂的大环pad4抑制剂
TW202140477A (zh) 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
MX2022013615A (es) 2020-04-30 2022-11-16 Gilead Sciences Inc Inhibidores de macrociclo de peptidilarginina deiminasas.
CN111943947B (zh) * 2020-07-24 2021-04-30 重庆文理学院 1H-吡咯[2,3-b]吡啶衍生物及其合成方法与应用
WO2022040267A1 (en) 2020-08-19 2022-02-24 Bristol-Myers Squibb Company 1h-pyrrolo[3,2-c]pyridine and 1h-pyrrolo[2,3-c]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis
US12492188B2 (en) 2020-08-19 2025-12-09 Bristol-Myers Squibb Company 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis
EP4267562A1 (en) * 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202233174A (zh) * 2020-12-22 2022-09-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
CN117427074B (zh) * 2023-11-13 2026-07-28 山东第一医科大学(山东省医学科学院) 四氢喹啉醇作为铁死亡抑制剂在制备急性肾损伤药物中的应用
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522628A (ja) 2012-07-26 2015-08-06 グラクソ グループ リミテッドGlaxo Group L Pad4阻害剤としての2−(アザインドール−2−イル)ベンズイミダゾール
WO2017100594A1 (en) 2015-12-09 2017-06-15 Padlock Therapeutics, Inc. Bicyclic inhibitors of pad4
WO2017100601A1 (en) 2015-12-09 2017-06-15 Padlock Therapeutics, Inc. Aza-benzimidazole inhibitors of pad4
JP2018520105A (ja) 2015-05-21 2018-07-26 グラクソスミスクライン、インテレクチュアル、プロパテ Pad4阻害剤としてのベンゾイミダゾール誘導体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602812B (zh) 2015-12-22 2021-11-02 坎塞拉有限公司 可用作哺乳动物组蛋白去乙酰化酶活性的抑制剂的双环异羟肟酸类化合物
SG11201807021UA (en) 2016-02-23 2018-09-27 Padlock Therapeutics Inc Heteroaryl inhibitors of pad4
US10703741B2 (en) 2016-07-27 2020-07-07 Padlock Therapeutics, Inc. Covalent inhibitors of PAD4
KR102502992B1 (ko) 2016-09-12 2023-02-24 패들락 테라퓨틱스, 인코포레이티드 Pad4의 헤테로아릴 억제제
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
MX2021001471A (es) 2018-08-08 2021-04-28 Bristol Myers Squibb Co Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
ES2929200T3 (es) 2018-08-08 2022-11-25 Bristol Myers Squibb Co Tienopirroles sustituidos como inhibidores de PAD4
EP3833440A1 (en) 2018-08-08 2021-06-16 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
ES2956090T3 (es) 2018-08-08 2023-12-13 Bristol Myers Squibb Co Inhibidores de bencimidazol de enzimas PAD

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522628A (ja) 2012-07-26 2015-08-06 グラクソ グループ リミテッドGlaxo Group L Pad4阻害剤としての2−(アザインドール−2−イル)ベンズイミダゾール
JP2018520105A (ja) 2015-05-21 2018-07-26 グラクソスミスクライン、インテレクチュアル、プロパテ Pad4阻害剤としてのベンゾイミダゾール誘導体
WO2017100594A1 (en) 2015-12-09 2017-06-15 Padlock Therapeutics, Inc. Bicyclic inhibitors of pad4
WO2017100601A1 (en) 2015-12-09 2017-06-15 Padlock Therapeutics, Inc. Aza-benzimidazole inhibitors of pad4

Also Published As

Publication number Publication date
KR20210042934A (ko) 2021-04-20
BR112021002091A2 (pt) 2021-05-04
CL2021000296A1 (es) 2021-06-25
CN112805067A (zh) 2021-05-14
AR115920A1 (es) 2021-03-10
KR102885181B1 (ko) 2025-11-11
EA202190462A1 (ru) 2021-06-03
SG11202101174RA (en) 2021-03-30
EP3833440A1 (en) 2021-06-16
TW202019415A (zh) 2020-06-01
PE20211068A1 (es) 2021-06-09
US11524959B1 (en) 2022-12-13
AU2019319835A1 (en) 2021-03-25
WO2020033520A1 (en) 2020-02-13
CO2021001217A2 (es) 2021-02-26
CN112805067B (zh) 2026-04-24
MX2021001565A (es) 2021-04-19
IL280650A (en) 2021-03-25
JP2021534108A (ja) 2021-12-09
CA3108791A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
KR102885181B1 (ko) Pad 효소의 인돌 및 아자인돌 억제제
JP7447080B2 (ja) Pad4阻害剤としての置換チエノピロール
JP7434281B2 (ja) Pad酵素のベンズイミダゾール阻害剤
TWI891649B (zh) 作為cd38抑制劑之雜雙環醯胺
KR102729670B1 (ko) Pad4의 비시클릭 억제제
JP7483678B2 (ja) Pad4阻害剤としての置換ベンズイミダゾール
JP7711073B2 (ja) 免疫抑制剤として有用な大環状pad4阻害剤
WO2024222835A1 (en) Sarm1 modulators, preparations, and uses thereof
WO2023230609A1 (en) Heterocyclic pad4 inhibitors
EP4531843A1 (en) Heterocyclic pad4 inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250313

R150 Certificate of patent or registration of utility model

Ref document number: 7651451

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150